Category: General News
Search News
Combining research and public engagement
8th April 2021
Fran Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, recently wrote a World View article for the journal Nature Reviews Cancer, discussing her dual career in public engagement and research.
Read more
Researchers use machine learning to rank cancer drugs in order of efficacy
25th March 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have developed a machine learning algorithm that ranks drugs based on their efficacy in reducing cancer cell growth. The approach may have the potential to advance personalised therapies in the future by allowing oncologists to select the best drugs to treat individual cancer patients.
Read more
Ovarian Cancer Perspectives: Q&A with Dr Michelle Lockley
18th March 2021
In recognition of Ovarian Cancer Awareness Month, we spoke with Dr Michelle Lockley, Group Leader and clinical researcher in BCI’s Centre for Cancer Cell and Molecular Biology. Dr Lockley’s research group focuses on improving treatments for women with ovarian cancer, particularly for those whose tumours are resistant to chemotherapy.
Read more
New class of drug reduces risk of death in bladder cancer
15th February 2021
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Professor Tom Powles from Barts Cancer Institute, Queen Mary University of London and Barts Health NHS Trust.
Read more
SNPnexus in the fight against COVID-19
8th February 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have released a web-based tool called SNPnexus COVID to streamline the analysis of host genetic sequencing data and allow for the identification and prioritisation of genetic variants that may impact an individual’s susceptibility to and the severity of COVID-19 infection.
Read more
Research highlighted in ASCO annual report on progress against cancer
2nd February 2021
Research led by Professors Peter Schmid and Thomas Powles from Barts Cancer Institute, Queen Mary University of London, has been selected by the American Society of Clinical Oncology (ASCO) for inclusion in the Clinical Cancer Advances 2021, the Society’s annual review of progress against cancer. The notable studies, which investigated the use of immunotherapy in the treatment of triple negative breast cancer and advanced bladder cancer, are featured as two of many remarkable milestones in clinical cancer research and care.
Read more